Does insurance cover Dupixent? Why eczema drugs get denied — and how to get approved

By Hemant Adhikari, founder of WillItCover · Digested from UnitedHealthcare, Cigna, Aetna and Anthem published policies · Last verified July 7, 2026

Why eczema drugs need prior authorization at all

Dupixent, Rinvoq, Cibinqo and Adbry are specialty drugs — they can run well over $3,000 a month at list price. So insurers put them on a specialty formulary tier and wrap them in prior authorization (PA): before the pharmacy can fill the prescription, your doctor has to submit documentation showing you meet the plan's clinical criteria. The good news is that those criteria are published and specific. A denial is rarely the end of the road — it's usually a signal that a particular box wasn't checked. Once you know which boxes the plan is looking at, the path to approval gets a lot clearer.

These are covered under your pharmacy benefit (the drug side of your plan), not the medical benefit — which matters because it means the fight is about the plan's drug-coverage rules, not about whether eczema itself is a covered condition.

The three gates that decide most cases

Across UnitedHealthcare, Cigna, Aetna and Anthem, the criteria for the eczema systemic drugs converge on the same three requirements. Miss any one and you get denied; document all three and approval usually follows.

1. Objective severity — "moderate-to-severe," measured

These drugs are approved and covered for moderate-to-severe disease, not mild or occasional eczema. Crucially, plans want the severity shown with a real measure, not an adjective. That means one or more of: the percentage of body surface area (BSA) affected, an EASI score (Eczema Area and Severity Index), or an IGA score (Investigator's Global Assessment). A chart note that just says "eczema, not well controlled" is one of the most common reasons a first submission bounces. A note that says "moderate-to-severe atopic dermatitis, ~18% BSA, IGA 3, significant sleep disruption" is much harder to deny.

2. Topical step therapy — the single most common denial reason

Before a systemic drug, plans require that you've already tried and failed (or can't tolerate, or have a contraindication to) topical prescription treatments. UnitedHealthcare's Dupixent policy, for example, requires a documented history of failure, contraindication, or intolerance to two of these topical classes:

• A medium-, high-, or very-high-potency topical corticosteroid (for example mometasone, fluocinolone, or fluocinonide)
• A topical calcineurin inhibitor — tacrolimus (Protopic) or pimecrolimus (Elidel)
• Eucrisa (crisaborole)

The key word is documented: the plan wants the drug name, the dates you used it, and the outcome (didn't work, caused side effects, or can't be used). This is the box that quietly sinks the most claims — people have genuinely tried topicals for years, but if it isn't written in the chart the way the policy asks, the request is denied for "step therapy not met."

3. A specialist prescriber

Most plans only approve these drugs when the prescriber is a dermatologist, allergist, or immunologist — or when a specialist is consulted. If your primary-care provider wrote the prescription, the plan may deny it until a specialist prescribes or co-signs. This one surprises people, because the PCP may know the case best, but the policy language is explicit.

How Dupixent, Rinvoq, Cibinqo and Adbry differ

All four share the severity + topical + specialist gates. The differences are in the details — age, drug type, and the extra hurdles for the oral JAK inhibitors.

The full list of reasons eczema drugs get denied

When a denial letter arrives, the stated reason is almost always one of these. Match it to the fix:

1. "Step therapy not met." The two topical classes weren't documented (or only one was). Fix: have the dermatologist add the drug names, dates, and outcomes for two topical classes — or note the contraindication.
2. "Severity not documented / criteria not met." No objective measure of moderate-to-severe disease. Fix: add a BSA %, EASI, or IGA score, plus the functional impact (sleep, work, itch).
3. "Prescriber requirement not met." A non-specialist wrote it. Fix: have a dermatologist, allergist, or immunologist prescribe or co-sign.
4. "Not on formulary" or "non-preferred." The plan prefers a different agent first. Fix: use the preferred drug, or request a formulary exception with a clinical rationale.
5. "Quantity limit exceeded." The dose or number of pens/tubes is above the plan's cap. Fix: a quantity-limit exception with the prescribing rationale.
6. Duplicate therapy. You're already on another biologic or JAK for the eczema. Fix: only one systemic agent at a time.
7. JAK-specific gaps. For Rinvoq or Cibinqo: missing TB screening, missing labs, or no biologic tried first. Fix: complete the screening and document a biologic trial or contraindication.
8. Age. A JAK inhibitor requested under age 12. Fix: for younger patients, Dupixent is the option approved down to 6 months.

How to get approved the first time

The whole game is getting the documentation right before the request is filed. A practical checklist:

• Get an objective severity score in the chart — BSA %, EASI, or IGA — plus a line on functional impact (sleep, itch, work or school).
• Document two topical classes — a medium/high-potency steroid and a calcineurin inhibitor or Eucrisa — with drug names, dates, and why each failed or can't be used.
• Confirm a specialist is prescribing or co-signing.
• For a JAK inhibitor (Rinvoq/Cibinqo), complete TB screening and baseline labs, and note any biologic tried first.
• Match the drug to the plan's preferred agent where possible — or be ready to request an exception.
• Ask the office to submit a complete PA packet, not a bare form — the more of the above that's attached up front, the fewer round trips.

You can run your exact situation through the free dermatology coverage checker to see which of these are met and which are still open before anything is submitted.

What to do if you're already denied — the appeal playbook

A denial is not a no; for these drugs it's often a "not yet." Most eczema-drug denials are overturned, and most overturns simply add the missing documentation. Here's the ladder:

1. Read the denial letter for the exact reason. It will name the specific criterion that wasn't met ("step therapy," "severity," "prescriber"). That tells you precisely what to supply — don't argue the whole case, fix the one gap.
2. Ask for a peer-to-peer review. Your dermatologist can speak directly with the plan's reviewing physician. For a clear-cut case with the right history, this often resolves it fastest.
3. File the internal appeal, on time. Attach the missing piece — the severity score, the record of the two topicals, or the specialist's sign-off. Watch the deadline in the letter (commonly 60–180 days for a standard appeal; expedited appeals exist if a delay would harm you).
4. Escalate to external review if it's upheld. If the internal appeal is denied, you're entitled to an independent external review by reviewers not employed by the plan — through your state's process for a state-regulated plan, or the federal external-review process for a self-funded employer plan. This is generally requested within about four months of the final internal denial, and the decision is binding on the insurer.
5. Use manufacturer support as a bridge. Programs like Dupixent MyWay and Rinvoq Complete can help with cost — and sometimes bridge supply — while the appeal is pending. (These help affordability; they don't replace the insurance PA.)

For clinicians and patient advocates

If you're helping someone get one of these approved, the highest-yield things to put in the chart are: an objective severity measure (BSA/EASI/IGA) with functional impact; a clean step-therapy history naming two topical classes with dates and outcomes; confirmation of a specialist prescriber; and, for JAK inhibitors, TB screening plus labs and any biologic trial. Submitting a complete packet up front — rather than the minimum form — is what turns a multi-round denial-and-appeal cycle into a first-pass approval. Patients can be pointed to a free tool that walks through exactly these criteria: the dermatology coverage checker.

Frequently asked questions

Related: Dermatology coverage checker · Is my drug on my plan's formulary? · Why prior authorizations get denied · Same drug, wrong form or dose — denied